Arbaclofen ( DrugBank: Arbaclofen )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 13 |
| 206 | 脆弱Ｘ症候群 | 4 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
Showing 1 to 10 of 13 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004100-22-HR (EUCTR) | 27/04/2018 | 16/05/2019 | Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004) A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Ef ... | Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Other descriptive name: AERT, (R)-Baclofen Product Name: ArbaclofenExtended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Ot ... | Osmotica Pharmaceutical US LLC | NULL | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of ... | ||
| 2 | EUCTR2017-004101-40-HR (EUCTR) | 27/04/2018 | 16/05/2019 | Long-Term Study of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity Long-Term Study of ArbaclofenExtended-Release Tablets in Multiple Sclerosis Patients with Spasticity ... | An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity (Study OS440-3005). An Open-Label Study to Evaluate the Long-Term Safety of ArbaclofenExtended-Release Tablets in Multip ... | Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Other descriptive name: AERT, (R)-Baclofen Product Name: ArbaclofenExtended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Ot ... | Osmotica Pharmaceutical US LLC | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | Serbia;Belarus;Bosnia and Herzegovina;Moldova, Republic of;Bulgaria;Russian Federation;Croatia;Ukraine;Poland;United States Serbia;Belarus;Bosnia and Herzegovina;Moldova, Republic of;Bulgaria;Russian Federation;Croatia;Ukrai ... | ||
| 3 | NCT03319732 (ClinicalTrials.gov) | April 3, 2018 | 13/10/2017 | A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS A Study to Evaluate the Long-term Safety of ArbaclofenExtended-Release Tablets for Patients With Spa ... | An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005) An Open-Label Study to Evaluate the Long-Term Safety of ArbaclofenExtended-Release Tablets in Multip ... | Multiple Sclerosis;Spasticity, Muscle | Drug: Arbaclofen | Osmotica Pharmaceutical US LLC | NULL | Active, not recruiting | 18 Years | 65 Years | All | 323 | Phase 3 | United States |
| 4 | EUCTR2017-004101-40-BG (EUCTR) | 23/03/2018 | 09/01/2018 | Long-Term Study of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity Long-Term Study of ArbaclofenExtended-Release Tablets in Multiple Sclerosis Patients with Spasticity ... | An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity (Study OS440-3005). An Open-Label Study to Evaluate the Long-Term Safety of ArbaclofenExtended-Release Tablets in Multip ... | Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Other descriptive name: AERT, (R)-Baclofen Product Name: ArbaclofenExtended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Ot ... | Osmotica Pharmaceutical US LLC | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | United States;Serbia;Belarus;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina United States;Serbia;Belarus;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of ... | ||
| 5 | EUCTR2017-004100-22-PL (EUCTR) | 21/03/2018 | 09/02/2018 | Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004) A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Ef ... | Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Other descriptive name: AERT, (R)-Baclofen Product Name: ArbaclofenExtended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Ot ... | Osmotica Pharmaceutical US LLC | NULL | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of ... | ||
| 6 | EUCTR2017-004101-40-PL (EUCTR) | 21/03/2018 | 12/02/2018 | Long-Term Study of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity Long-Term Study of ArbaclofenExtended-Release Tablets in Multiple Sclerosis Patients with Spasticity ... | An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity (Study OS440-3005). An Open-Label Study to Evaluate the Long-Term Safety of ArbaclofenExtended-Release Tablets in Multip ... | Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Other descriptive name: AERT, (R)-Baclofen Product Name: ArbaclofenExtended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Ot ... | Osmotica Pharmaceutical US LLC | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | United States;Serbia;Belarus;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina United States;Serbia;Belarus;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of ... | ||
| 7 | EUCTR2017-004100-22-BG (EUCTR) | 16/03/2018 | 08/01/2018 | Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004) A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Ef ... | Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Spasticity in patients with multiple sclerosis MedDRA version: 20.0;Level: LLT;Classification code 1 ... | Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Other descriptive name: AERT, (R)-Baclofen Product Name: ArbaclofenExtended Release Tablets Product Code: OS440 INN or Proposed INN: Arbaclofen Ot ... | Osmotica Pharmaceutical US LLC | NULL | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | United States;Serbia;Belarus;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina United States;Serbia;Belarus;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of ... | ||
| 8 | NCT03290131 (ClinicalTrials.gov) | January 28, 2018 | 19/9/2017 | A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS A Study to Investigate the Safety and Effectiveness of ArbaclofenExtended-Release Tablets for Patien ... | A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Ef ... | Multiple Sclerosis;Spasticity, Muscle | Drug: Arbaclofen;Drug: Placebo | Osmotica Pharmaceutical US LLC | NULL | Completed | 18 Years | 65 Years | All | 536 | Phase 3 | Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Serbia;United States |
| 9 | NCT02869425 (ClinicalTrials.gov) | July 2016 | 3/8/2016 | To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS To Assess Effects of ArbaclofenER Tablets Compared With Placebo on Sperm Parameters in Male Subjects ... | A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of ArbaclofenER Tablets Compa ... | Multiple Sclerosis;Sperm | Drug: arbaclofen ER Tablets;Drug: Placebo for arbaclofen ER tablets | Osmotica Pharmaceutical US LLC | NULL | Withdrawn | 18 Years | 55 Years | Male | 0 | Phase 3 | United States |
| 10 | NCT01844232 (ClinicalTrials.gov) | April 2013 | 24/4/2013 | One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects Wit ... | A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of ArbaclofenExtended ... | Multiple Sclerosis;Spasticity | Drug: arbaclofen | Osmotica Pharmaceutical US LLC | NULL | Completed | 18 Years | 70 Years | All | 150 | Phase 3 | United States;Russian Federation;Ukraine |
206. 脆弱Ｘ症候群
臨床試験数 : 104 / 薬物数 : 87 - (DrugBank : 32) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 79
Showing 1 to 4 of 4 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01555333 (ClinicalTrials.gov) | November 2011 | 1/3/2012 | An Open Label Extension Study in Subjects With Fragile X Syndrome | An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject ... | Fragile X Syndrome | Drug: arbaclofen | Seaside Therapeutics, Inc. | NULL | Terminated | 5 Years | 50 Years | Both | 357 | Phase 3 | United States |
| 2 | NCT01325220 (ClinicalTrials.gov) | June 2011 | 28/3/2011 | Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children ... | A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolera ... | Fragile X Syndrome | Drug: arbaclofen;Drug: Placebo | Seaside Therapeutics, Inc. | NULL | Completed | 5 Years | 11 Years | Both | 172 | Phase 3 | United States |
| 3 | NCT01282268 (ClinicalTrials.gov) | May 2011 | 20/1/2011 | Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults Wit ... | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of ST ... | Fragile X Syndrome | Drug: arbaclofen;Drug: placebo | Seaside Therapeutics, Inc. | NULL | Completed | 12 Years | 50 Years | Both | 125 | Phase 3 | United States |
| 4 | NCT01013480 (ClinicalTrials.gov) | November 2009 | 12/11/2009 | An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome | An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Fragile X Syndrome An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in ... | Fragile X Syndrome | Drug: Arbaclofen | Seaside Therapeutics, Inc. | NULL | Terminated | 6 Years | 40 Years | Both | 45 | Phase 2 | United States |